REG - Diaceutics PLC - Results of AGM

DiaceuticsAnnouncement

18/06/2025 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250618:nRSR3999Na&default-theme=true

RNS Number : 3999N  Diaceutics PLC  18 June 2025

Diaceutics PLC - Results of AGM

New York, Belfast and London, 18 June 2025 - Diaceutics PLC
(https://www.diaceutics.com/)  (AIM: DXRX), a leading technology and
solutions provider to the pharma and biotech industry, is pleased to announce
that all resolutions proposed at its Annual General Meeting held earlier
today, were duly passed. The proxy votes received from shareholders in respect
of each resolution are set out below and are available on the Company's
website www.diaceutics.com (http://www.diaceutics.com)

 Resolution                                                                              For (excluding at Chair's discretion)     Against                  Total votes cast   Withheld
                                                                                         Number of votes      %                    Number of votes  %       Number of votes    Number of votes
 1       Ordinary resolution to receive To receive and consider the Company's financial  54,937,420           99.99%               577              0.01%   54,937,997         Nil
         statements for the financial year ended 31 December 2024 together with the
         directors' report and the auditors' report on those annual accounts
 2       Ordinary resolution to approve the directors' remuneration report               44,895,272           83.09%               9,136,725        16.91%  54,937,997         906,000
 3       Ordinary resolution to re-elect Cheryl MacDiarmid as a director of the Company  54,937,420           99.99%               577              0.01%   54,937,997         Nil
 4       Ordinary resolution to re-elect Jordan Clark as a director of the Company       51,811,362           99.98%               11,300           0.02%   54,937,997         3,115,335
 5       Ordinary resolution to re-elect Nick Roberts as a director of the Company       51,639,642           99.65%               183,020          0.35%   54,937,997         3,115,335
 6       Ordinary resolution to re-appoint Ernst & Young as auditors of the              54,925,512           99.98%               12,485           0.02%   54,937,997         Nil
         Company
 7       Ordinary resolution to authorise the directors to determine the remuneration    54,937,420           99.99%               577              0.01%   54,937,997         Nil
         of the auditors
 8       Ordinary resolution to authorise the directors to allot ordinary shares         54,905,822           99.94%               32,175           0.06%   54,937,997         Nil
 9       Special resolution to authorise the directors to dis-apply statutory            53,670,136           99.92%               44,461           0.08%   54,937,997         1,223,400
         pre-emption rights pursuant to section 570 of the Companies Act 2006
 10      Special resolution to authorise the directors to make market purchase of its    52,510,452           99.99%               577              0.01%   54,937,997         2,426,968

       ordinary shares

 11      Ordinary resolution to approve The Diaceutics Unapproved Share Option Plan      51,312,153           93.40%               3,625,844        6.60%   54,937,997         Nil

 

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGGPURCQUPAUBR